You keep copy-pasting the same debunked talking points like they’re gospel
- No land access — False. TMG’s ACP project sits on patented mining claims in Utah, meaning they own the land rights. This isn’t federal BLM land. There’s no access issue.
- No permits — It’s early-stage development, yes — but Utah is one of the most mining-friendly jurisdictions in the U.S. for critical minerals. Permits come with time and planning
- Hundreds of millions required — Maybe over the life of mine, but staged development is how every mine works. You think Lynas or MP Materials raised a billion on day one? Strategic assets attract funding, especially when they’re the only U.S. source of a critical missile metal.
- Years off from mining — And? Most majors take 7–10 years from discovery to production. But value is created in the de-risking stages. If you wait for first production, you’ll be buying at 100x the current valuation.
- Antimony demand will be satisfied? With what, exactly? 90% still comes from China and Russia. The U.S. has zero domestic production. The DoD and DOE are actively hunting for reliable Western supply — and TMG sits right in the heart.
- Comparing this to latecomer lithium plays is a lazy take. Antimony is not a bulk battery commodity — it’s a defence-critical, supply-constrained strategic metal. Totally different market structure, pricing, and geopolitical leverage.
So yeah, TMG is undervalued. Not because it’s producing tomorrow, but because it holds a one-of-a-kind asset that aligns with national security, decarbonisation, and supply chain independence.Maybe the real ‘bias’ here is yours — ignoring fundamentals to keep pushing fear
- Forums
- ASX - By Stock
- TMG
- chart
TMG
trigg minerals limited
Add to My Watchlist
0.00%
!
9.8¢

chart, page-2215
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
9.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $91.26M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 112862 | 10.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.9¢ | 162911 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 112862 | 0.105 |
3 | 650000 | 0.100 |
2 | 30000 | 0.099 |
2 | 302040 | 0.098 |
1 | 50000 | 0.096 |
Price($) | Vol. | No. |
---|---|---|
0.099 | 162911 | 2 |
0.100 | 379161 | 7 |
0.105 | 3130617 | 21 |
0.110 | 447252 | 11 |
0.115 | 1413669 | 6 |
Last trade - 16.20pm 27/06/2025 (20 minute delay) ? |
Featured News
TMG (ASX) Chart |
Day chart unavailable
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online